The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Chemotherapy Plus Radiation Therapy in Treating Patients With Primary Stage IVB Cervical Cancer
Official Title: Chemotherapy Plus Radiation Therapy in Treating Patients With Primary Stage IVB Cervical Cancer: A Prospective, Single Arm, Phase II Clinical Trial
Study ID: NCT03175848
Brief Summary: This is a prospective, single arm, phase II trail to assess the effect of primary lesion radiotherapy in the treatment of stage IVB cervical cancer on the basis of systemic chemotherapy.
Detailed Description: Because of the apparent heterogeneity of stage IVB cervical cancer, at present there is no standard treatment. This is a Phase II, single-center, single-arm, study of systemic chemotherapy plus lesion radiotherapy for primary stage IVB cervical cancer. The primary objective of the study is to test the hypothesis that primary lesion radiotherapy leads to an improvement in progression-free survival time (PFS)for stage IVB cervical cancer. For those patients under the clinical management of the recruiting investigator, the investigator will review the patient's medical records and determine if they would be a candidate for the study. Upon confirmation of all eligibility criteria, the subject will be enrolled.Patients with beyond abdominal pelvic lymph node metastasis will first undergo 2 cycle systemic chemotherapy(TP/TC),then to evaluate the efficacy of chemotherapy, and for patients with chemotherapy effective(CR+PR+SD) followed by the primary lesion of regional radiotherapy (external irradiation plus brachytherapy),concurrent chemotherapy (TP/TC) may be given according to the patients tolerant,finally, the patient will complete a total of 6 cycles of chemotherapy(TP/TC).Distant metastasis of lymph node areas (e.g., supraclavicular, axillary, mediastinum, etc.) will be radiation after radiotherapy at the primary site according to patients tolerant.Patients with stage IVB cervical cancer with hematogenous metastasiswill first undergo 4 cycle systemic chemotherapy(TP/TC),then to evaluate the efficacy of chemotherapy, and for patients with chemotherapy effective(CR+PR+SD) followed by the primary lesion of regional radiotherapy (external irradiation plus brachytherapy),concurrent chemotherapy (TP/TC) may be given according to the patients tolerant,finally, the patient will complete a total of 6 cycles of chemotherapy(TP/TC),after the primary radiotherapy, the treatment regimen for distant metastasis will be determined by MDT discuss or consultation.Quality of life will be evaluated before and after treatment. During therapy, the patient will have a weekly physical exam, vital signs collected, evaluation for pain, and review any side effects. Subjects will undergo a post treatment follow-up period after completion of their radiation therapy. During this follow-up period, subjects will return for a medical and history review with a complete physical examination, review of any side effects, evaluation for outcomes and toxicity, and QoL.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Name: HanMei Lou, M.A.
Affiliation: Zhejiang Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: ZhuoMin Yin
Affiliation: Zhejiang Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR